Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer announces cardiovascular risk research programme

Pfizer announces cardiovascular risk research programme

24th September 2007

Pfizer has announced a joint awards initiative with the European Foundation for the Study of Diabetes (EFSD) for the provision of research grants to support programmes exploring the reduction of cardiovascular risk in diabetes patients.

The firm announced at the annual meeting of the European Association for the Study of Diabetes that these grants will be focused on educational schemes, the use of screening and risk-assessment tools and other research efforts promoting an improved understanding of risk-reduction strategies in this area.

Scientists interested in applying for a research grant have been advised to check the instructions in a forthcoming issue of the Diabetologia journal, with applications open from January 2008 with a March 2008 deadline.

Dr Lance Berman, senior medical director at Pfizer, said: “As part of our commitment to the care of patients with diabetes, Pfizer is dedicated to supporting research that will help identify ways to reduce these risks, further our understanding of optimal treatment options and ultimately improve the lives of the people with diabetes.”

He added that the company is proud to join with the EFSD in the offering of this research grant programme.

Earlier this month, Pfizer released clinical trial data suggesting that patients moving away from using Lipitor saw a 30 per cent rise in the risk of experiencing a cardiovascular event.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.